4th quarter 2015 was the best quarter ever for
Medistim and sales ended at MNOK 74.6 (MNOK 66.1), a
growth of 12.9 %. Sales for 2015 ended at MNOK 251.4
(MNOK 214.8), a growth of 17.0 %. Operating profit
(EBIT) for the quarter ended at MNOK 16.0 (MNOK 14.5).
Operating profit for 2015 ended at MNOK 50.3 (MNOK
43.4).
Sales team in the US is increased with 5 sales
representatives in 2015. Sales in the US increased
with 15.7 % for the quarter and 34.8 % for the year.
Medistim entered a strategic agreement with em-tec in
the 4th quarter. The combined flow and ultrasound
imaging study REQUEST has enrolled >200 patients by
the end of 2015.
The Board suggests a dividend of NOK 1,65 per share
(NOK 1.40)